WINTON GROUP Ltd acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 105,191 shares of the medical equipment provider’s stock, valued at approximately $3,068,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Acrospire Investment Management LLC grew its position in shares of Boston Scientific by 157.3% in the 2nd quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock valued at $141,000 after buying an additional 3,100 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its position in shares of Boston Scientific by 14.3% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock valued at $160,000 after buying an additional 720 shares during the last quarter. San Francisco Sentry Investment Group CA purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $191,000. Peddock Capital Advisors LLC purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $201,000. Finally, Ironwood Investment Counsel LLC purchased a new position in shares of Boston Scientific in the 3rd quarter valued at $204,000. Institutional investors and hedge funds own 90.55% of the company’s stock.

A number of research analysts recently commented on BSX shares. BidaskClub downgraded shares of Boston Scientific from a “hold” rating to a “sell” rating in a research report on Saturday, August 26th. BMO Capital Markets increased their target price on shares of Boston Scientific from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research report on Monday, September 25th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a research report on Friday, September 1st. Finally, Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Boston Scientific has an average rating of “Buy” and a consensus target price of $30.61.

Boston Scientific Corporation (BSX) opened at $26.15 on Friday. Boston Scientific Corporation has a 52-week low of $20.03 and a 52-week high of $29.93. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The stock has a market cap of $35,910.00, a price-to-earnings ratio of 21.54, a price-to-earnings-growth ratio of 2.03 and a beta of 0.99.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period last year, the firm posted $0.27 EPS. Boston Scientific’s revenue for the quarter was up 5.6% on a year-over-year basis. equities analysts anticipate that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.

In other news, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $28.72, for a total value of $445,160.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Timothy A. Pratt sold 11,061 shares of Boston Scientific stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the sale, the executive vice president now directly owns 174,681 shares in the company, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. Insiders have sold a total of 414,698 shares of company stock worth $12,013,153 over the last three months. 0.74% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/12/02/winton-group-ltd-invests-3-07-million-in-boston-scientific-corporation-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.